Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) FCF Margin (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed FCF Margin for 6 consecutive years, with 173.76% as the latest value for Q1 2025.

  • Quarterly FCF Margin rose 20719.0% to 173.76% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 1371.38% through Dec 2025, down 113582.0% year-over-year, with the annual reading at 1371.38% for FY2025, 113582.0% down from the prior year.
  • FCF Margin for Q1 2025 was 173.76% at Whitehawk Therapeutics, up from 210.51% in the prior quarter.
  • The five-year high for FCF Margin was 8802.5% in Q1 2021, with the low at 842.57% in Q1 2022.
  • Average FCF Margin over 5 years is 329.54%, with a median of 217.87% recorded in 2022.
  • The sharpest move saw FCF Margin plummeted -964507bps in 2022, then surged 45601bps in 2023.
  • Over 5 years, FCF Margin stood at 89.1% in 2021, then plummeted by -145bps to 217.87% in 2022, then grew by 24bps to 165.35% in 2023, then dropped by -27bps to 210.51% in 2024, then grew by 17bps to 173.76% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 173.76%, 210.51%, and 220.12% for Q1 2025, Q4 2024, and Q3 2024 respectively.